PhaseRx (PZRX) Receives Daily News Sentiment Score of -0.03

News stories about PhaseRx (NASDAQ:PZRX) have been trending somewhat negative on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PhaseRx earned a media sentiment score of -0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.3431194105209 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of PhaseRx (PZRX) traded down $0.01 during mid-day trading on Wednesday, hitting $0.35. 435,900 shares of the stock traded hands, compared to its average volume of 216,350. The stock has a market capitalization of $4.09 and a P/E ratio of -0.29. The company has a debt-to-equity ratio of -12.03, a quick ratio of 2.14 and a current ratio of 2.14. PhaseRx has a 52 week low of $0.22 and a 52 week high of $1.95.

PhaseRx (NASDAQ:PZRX) last announced its earnings results on Thursday, November 9th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.14.

Separately, Laidlaw downgraded shares of PhaseRx from a “buy” rating to a “neutral” rating in a report on Friday, October 13th.

WARNING: “PhaseRx (PZRX) Receives Daily News Sentiment Score of -0.03” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at

About PhaseRx

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

Insider Buying and Selling by Quarter for PhaseRx (NASDAQ:PZRX)

Receive News & Ratings for PhaseRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit